JP2022513402A5 - - Google Patents
Info
- Publication number
- JP2022513402A5 JP2022513402A5 JP2021548536A JP2021548536A JP2022513402A5 JP 2022513402 A5 JP2022513402 A5 JP 2022513402A5 JP 2021548536 A JP2021548536 A JP 2021548536A JP 2021548536 A JP2021548536 A JP 2021548536A JP 2022513402 A5 JP2022513402 A5 JP 2022513402A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- expression
- bispecific molecule
- gene
- signature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024139452A JP2024178163A (ja) | 2018-10-30 | 2024-08-21 | 血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752659P | 2018-10-30 | 2018-10-30 | |
| US62/752,659 | 2018-10-30 | ||
| US201862769078P | 2018-11-19 | 2018-11-19 | |
| US62/769,078 | 2018-11-19 | ||
| US201962878368P | 2019-07-25 | 2019-07-25 | |
| US62/878,368 | 2019-07-25 | ||
| PCT/US2019/058616 WO2020092404A1 (en) | 2018-10-30 | 2019-10-29 | Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024139452A Division JP2024178163A (ja) | 2018-10-30 | 2024-08-21 | 血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513402A JP2022513402A (ja) | 2022-02-07 |
| JP2022513402A5 true JP2022513402A5 (enExample) | 2022-10-26 |
| JP7551066B2 JP7551066B2 (ja) | 2024-09-17 |
Family
ID=70464448
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548536A Active JP7551066B2 (ja) | 2018-10-30 | 2019-10-29 | 血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ |
| JP2024139452A Pending JP2024178163A (ja) | 2018-10-30 | 2024-08-21 | 血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024139452A Pending JP2024178163A (ja) | 2018-10-30 | 2024-08-21 | 血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210395374A1 (enExample) |
| EP (1) | EP3873606A4 (enExample) |
| JP (2) | JP7551066B2 (enExample) |
| KR (1) | KR102943465B1 (enExample) |
| CN (3) | CN113286633A (enExample) |
| AU (1) | AU2019371243A1 (enExample) |
| BR (1) | BR112021008283A2 (enExample) |
| CA (1) | CA3118081A1 (enExample) |
| IL (1) | IL282827A (enExample) |
| MX (1) | MX2021004868A (enExample) |
| SG (1) | SG11202104367RA (enExample) |
| WO (1) | WO2020092404A1 (enExample) |
| ZA (1) | ZA202102775B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022025834A2 (pt) * | 2020-06-18 | 2023-01-10 | Macrogenics Inc | Método para determinar se um paciente seria um respondedor adequado ao uso de uma molécula biespecífica cd123 x cd3 para tratar uma malignidade hematológica e método de tratamento de uma malignidade hematológica |
| AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| TW202241469A (zh) * | 2021-02-20 | 2022-11-01 | 美商凱特製藥公司 | 免疫療法 |
| WO2023092119A2 (en) * | 2021-11-22 | 2023-05-25 | Ludwig Institute For Cancer Research Ltd | Methods for predicting responsiveness to a cancer therapy |
| EP4499683A1 (en) * | 2022-03-29 | 2025-02-05 | NGM Biopharmaceuticals, Inc. | Ilt3 and cd3 binding agents and methods of use thereof |
| EP4507790A1 (en) | 2022-04-11 | 2025-02-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| CN120857940A (zh) | 2023-02-17 | 2025-10-28 | 瑞泽恩制药公司 | 对cd3/taa双特异性抗体有反应的诱导型nk细胞 |
| KR20250134857A (ko) * | 2024-03-05 | 2025-09-12 | 사회복지법인 삼성생명공익재단 | 비소세포폐암 환자의 면역 관문 억제제에 대한 반응성을 예측하는 방법, 장치, 및 컴퓨터프로그램 |
| CN120866362B (zh) * | 2025-07-15 | 2026-03-31 | 郑州大学第一附属医院 | 过表达ifitm2基因的car-t细胞、构建方法及其在免疫细胞疗法中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005201935B2 (en) * | 2004-05-06 | 2012-04-26 | Veridex, Llc | Prognostic for hematological malignancy |
| US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| US20160272720A1 (en) * | 2013-11-06 | 2016-09-22 | Memorial Sloan-Kettering Cancer Center | Compositions and Methods for the Treatment of Acute Myeloid Leukemias and Myelodysplastic Syndromes |
| PL3119807T3 (pl) * | 2014-03-19 | 2019-09-30 | Cellectis | Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów |
| JP2018538247A (ja) | 2015-10-23 | 2018-12-27 | 第一三共株式会社 | Ａｍｌを処置することに用いるための医薬組成物およびそれを必要とする対象においてａｍｌを処置する方法 |
| MX2018014950A (es) * | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| TWI790206B (zh) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| WO2019050521A1 (en) * | 2017-09-07 | 2019-03-14 | Macrogenics, Inc. | DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES |
-
2019
- 2019-10-29 AU AU2019371243A patent/AU2019371243A1/en active Pending
- 2019-10-29 US US17/290,061 patent/US20210395374A1/en active Pending
- 2019-10-29 KR KR1020217014961A patent/KR102943465B1/ko active Active
- 2019-10-29 EP EP19878838.2A patent/EP3873606A4/en active Pending
- 2019-10-29 CN CN201980087139.5A patent/CN113286633A/zh active Pending
- 2019-10-29 MX MX2021004868A patent/MX2021004868A/es unknown
- 2019-10-29 SG SG11202104367RA patent/SG11202104367RA/en unknown
- 2019-10-29 BR BR112021008283-2A patent/BR112021008283A2/pt unknown
- 2019-10-29 CN CN202411135769.4A patent/CN119236065A/zh active Pending
- 2019-10-29 CA CA3118081A patent/CA3118081A1/en active Pending
- 2019-10-29 WO PCT/US2019/058616 patent/WO2020092404A1/en not_active Ceased
- 2019-10-29 CN CN202411135807.6A patent/CN119280393A/zh active Pending
- 2019-10-29 JP JP2021548536A patent/JP7551066B2/ja active Active
-
2021
- 2021-04-26 ZA ZA2021/02775A patent/ZA202102775B/en unknown
- 2021-04-29 IL IL282827A patent/IL282827A/en unknown
-
2024
- 2024-08-21 JP JP2024139452A patent/JP2024178163A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022513402A5 (enExample) | ||
| US12152075B2 (en) | Treatment of renal cell carcinoma | |
| EP3879535B1 (en) | Systems and methods for identifying cancer treatments from normalized biomarker scores | |
| Roux et al. | Brucella requires a functional Type IV secretion system to elicit innate immune responses in mice | |
| RU2527068C2 (ru) | Фармакодинамические маркеры, индуцированные интерфероном альфа | |
| US11559574B2 (en) | Whole-cell cancer vaccines and methods for selection thereof | |
| CN101999001B (zh) | 疾病标志物及其用途 | |
| Aryankalayil et al. | Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells | |
| Lopes et al. | Temporal profiling of cytokine-induced genes in pancreatic β-cells by meta-analysis and network inference | |
| Hakim et al. | Upregulation of IFN-inducible and damage-response pathways in chronic graft-versus-host disease | |
| Muls et al. | IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy | |
| US12009079B2 (en) | Type I interferon signatures and methods of use | |
| JP2021525236A5 (enExample) | ||
| Du et al. | Pathway analysis of global gene expression change in dendritic cells induced by the polysaccharide from the roots of Actinidia eriantha | |
| US20210395374A1 (en) | Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies | |
| US11581059B2 (en) | Method of predicting graft versus host disease | |
| Paunovic et al. | Autophagy-independent increase of ATG5 expression in T cells of multiple sclerosis patients | |
| US20160159918A1 (en) | Methods for diagnosing and treating immune disease | |
| Chen et al. | The alteration and clinical significance of Th22/Th17/Th1 cells in patients with chronic myeloid leukemia | |
| JP2023505203A5 (enExample) | ||
| Tahrali et al. | CD3-CD56+ NK cells display an inflammatory profile in RR-MS patients | |
| Sahay et al. | Induction of interleukin 10 by Borrelia burgdorferi is regulated by the action of CD14-dependent p38 mitogen-activated protein kinase and cAMP-mediated chromatin remodeling | |
| Wang et al. | Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma | |
| Singh et al. | Dynamic single-cell RNA sequencing reveals BCG vaccination curtails SARS-CoV-2 induced disease severity and lung inflammation | |
| CA3214379A1 (en) | Treatments for prurigo nodularis |